QUOTE AND NEWS
Motley Fool  May 5  Comment 
The biotech is setting itself up nicely for "break even or better on a non-GAAP basis" in 2017.
Forbes  May 5  Comment 
In early trading on Thursday, shares of Discovery Communications (DISCA) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 6.0%. Year to date, Discovery Communications registers a 5.6% gain.
newratings.com  May 4  Comment 
DUBLIN (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) expects to submit EU and U.S. Marketing Application for Cerliponase alfa, intended for the treatment of children with CLN2 disease, a form of Batten disease, by mid-2016. The company's...
Forbes  Apr 20  Comment 
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Norfolk Southern Corp. (NYSE: NSC), where a total volume of 16,622 contracts has been traded thus far today, a contract volume...
Benzinga  Apr 20  Comment 
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) shares rose 4.7 percent after the company reported the findings from the Phase 2 trial offered evidence of durability of effect consistent with the earlier presented six-month data for those patients....
Forbes  Apr 20  Comment 
In early trading on Wednesday, shares of BioMarin Pharmaceutical (BMRN) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 5.3%.  Year to date, BioMarin Pharmaceutical has lost about 13.2% of its value.
newratings.com  Apr 20  Comment 
LONDON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced encouraging preliminary data from an ongoing Phase 1/2 clinical trial with BMN 270, an investigational gene therapy treatment for hemophilia A. The company said that a total of...
Forbes  Apr 19  Comment 
Investors in BioMarin Pharmaceutical Inc. (NASD: BMRN) saw new options become available this week, for the June 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BMRN options chain for the new June 17th...
Motley Fool  Mar 29  Comment 
Here's a brief overview of a rare-disease pioneer for investors unfamiliar with BioMarin, or its niche.




 

BioMarin Pharmaceutical Inc. (BMRN), a developer of enzyme-related therapies (ERT), co-markets Aldurazyme with Genzyme Corporation (GENZ) for the treatment of MPS-I (mucopolysaccharidosis). MPS-I is a rare genetic enzyme deficiency disorder, afflicting roughly 3,000 people worldwide, caused by the lack of a specific enzyme involved in lysosomal storage. More common names for mucopolysaccharidosis are Hurler's Syndrome, Hurler-Scheie, and Scheie's Disease. The company's other developed product, Naglazyme, for MPS-VI, recently entered the market. MPS-VI is also a rare genetic enzyme deficiency disorder, with an estimated 1,100 people suffering from it worldwide. The company's third lead drug, Kuvan, received FDA approval for the treatment of PKU in December 2007. With the recent launch of Kuvan, the company now has three products on the market. The company also receives royalties and license revenue on sales of the Orapred franchise from Alliant Pharmaceuticals. In 2004, the company acquired Orapred, a grape-flavored oral corticosteroid liquid for the treatment of severe asthma in children and subsequently licensed the franchise to Alliant Pharmaceuticals in March 2006. BioMarin, headquartered in Novato, CA, employs roughly 300 people.

Business Overview

Business & Financial Metrics

In 2009, BMRN incurred a net loss of $488 thousand on revenues of $324.7 million. This represents a real turnaround from 2008, when the company earned $30.8 million on $296.5 million in revenues.[1]

Geographical Distribution[2]

BioMarin generates the majority of its revenues from sales in Europe.

IMAGE:BMRN-Geography2009.jpg[2]

Competition

BioMarin competes with companies like:

References

  1. BMRN 2009 10-K pg. 36  
  2. 2.0 2.1 BMRN 2009 10-K pg. 16  
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki